**Author details**

Arli Aditya Parikesit Department of Bioinformatics, School of Life Sciences, Indonesia International Institute for Life Sciences, Jl. Pulomas Barat Kav.88, Jakarta, 13210, Indonesia

\*Address all correspondence to: arli.parikesit@i3l.ac.id

© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**7**

*Introductory Chapter: The Emerging Corner of the Omics Studies for Rational Drug Design*

Biotechnol. 25 (2020). https://doi. org/10.22146/ijbiotech.55631.

[9] P.J. Kaboli, A. Rahmat, P. Ismail, K.-H. Ling, MicroRNA-based therapy and breast cancer: A comprehensive review of novel therapeutic strategies

[10] M. Fan, R. Krutilina, J. Sun, A. Sethuraman, C.H. Yang, Z.-H. Wu, J. Yue, L.M. Pfeffer, Comprehensive analysis of microRNA (miRNA) targets in breast cancer cells., J. Biol. Chem. 288 (2013) 27480-27493. https://doi. org/10.1074/jbc.M113.491803.

[11] R. Wijaya, A.A. Parikesit, R. Nurdiansyah, 3D And 2D RNA Structure Prediction Of The BRCA2 Gene And Its Silencing RNA In The Breast Cancer, Walisongo J. Chem. 3 (2020) 10. https://doi.org/10.21580/wjc.

[12] M. Sahlan, M.N.H. Al Faris, R. Aditama, K. Lischer, A.C. Khayrani, D.K. Pratami, Molecular Docking of South Sulawesi Propolis against Fructose 1,6-Bisphosphatase as a Type 2 Diabetes Mellitus Drug, Int. J. Technol. 11 (2020) 910. https://doi.org/10.14716/

from diagnosis to treatment., Pharmacol. Res. 97 (2015) 104- 121. https://doi.org/10.1016/j.

phrs.2015.04.015.

v3i1.6019.

ijtech.v11i5.4332.

jksus.2020.101234.

[14] A.J. Gandhi, J.D. Rupareliya, V.J. Shukla, S.B. Donga, R. Acharya, An ayurvedic perspective along

[13] M. Sahlan, R. Irdiani, D.

Flamandita, R. Aditama, S. Alfarraj, M.J. Ansari, A.C. Khayrani, D.K. Pratami, K. Lischer, Molecular interaction analysis of Sulawesi propolis compounds with SARS-CoV-2 main protease as preliminary study for COVID-19 drug discovery., J. King Saud Univ. Sci. 33 (2021) 101234. https://doi.org/10.1016/j.

*DOI: http://dx.doi.org/10.5772/intechopen.95544*

[1] J.H. Martin, N.A. Bowden, Drug repurposing in the era of COVID-19: a call for leadership and government investment, Med. J. Aust. 212 (2020) 450-452.e1. https://doi.org/10.5694/

[2] D.J. Payne, L.F. Miller, D. Findlay, J. Anderson, L. Marks, Time for a change: addressing R&D and commercialization challenges for antibacterials, Philos. Trans. R. Soc. B Biol. Sci. 370 (2015) 20140086. https:// doi.org/10.1098/rstb.2014.0086.

[3] M. Gadebusch Bondio, M. Marloth, The "Historic Study" SOLIDARITY— Research's Answer to the Sars-CoV-2 Pandemic, NTM Int. J. Hist. Ethics Nat. Sci. Technol. Med. (2020). https://doi. org/10.1007/s00048-020-00257-5.

[4] F.K. Yoshimoto, The Proteins of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2 or n-COV19), the Cause of COVID-19, Protein J. 39 (2020) 198-216. https://doi. org/10.1007/s10930-020-09901-4.

[5] A.A. Parikesit, R. Nurdiansyah, The Predicted Structure for the Anti-Sense siRNA of the RNA Polymerase Enzyme (RdRp) gene of the SARS-CoV-2, Ber. Biol. 19 (2020) 97-108. https://doi. org/10.14203/beritabiologi.v19i1.3849.

[6] H. Uludağ, K. Parent, H.M. Aliabadi, A. Haddadi, Prospects for RNAi Therapy of COVID-19, Front. Bioeng. Biotechnol. (2020). https://doi.

org/10.3389/fbioe.2020.00916.

[7] K. Lundstrom, Viral vectors applied for RNAi-based antiviral therapy, Viruses. (2020). https://doi.

[8] J. Ivan, R. Nurdiansyah, A.A. Parikesit, Computational modeling of AGO-mediated molecular inhibition of ARF6 by miR-145, Indones. J.

org/10.3390/v12090924.

mja2.50603.

**References**

*Introductory Chapter: The Emerging Corner of the Omics Studies for Rational Drug Design DOI: http://dx.doi.org/10.5772/intechopen.95544*
